Methods of determining cellular chemosensitivity
US-9540674-B2 · Jan 10, 2017 · US
BH3 peptides and method of use thereof
US9856303B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9856303-B2 |
| Application number | US-96682110-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 13, 2010 |
| Priority date | Sep 9, 2002 |
| Publication date | Jan 2, 2018 |
| Grant date | Jan 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of screening for an apoptotic sensitizer compound comprising: (a) contacting mitochondria from a cell that overexpresses BCL-2 or BCL-XL with an isolated BH3 peptide comprising SEQ ID NO: 1 to form a BCL-2-peptide complex or a BCL-XL-peptide complex, wherein the BH3 peptide is less than or equal to 35 amino acids in length, and wherein the BH3 peptide when displaced from the complex activates pro-apoptotic BAK to thereby induce BAK oligomerization and cytochrome c release; (b) contacting said complex with a candidate apoptotic sensitizer compound that does not activate pro-apoptotic BAK; and (c) determining cytochrome c release from said mitochondria, wherein an increase in the amount of cytochrome c release in the presence of said candidate apoptotic sensitizer compound compared to the amount of cytochrome c release in the absence of said compound indicates said compound is an apoptotic sensitizer compound that displaces the BH3 peptide from the BCL-2-peptide complex or the BCL-XL-peptide complex. 2. The method of claim 1 , wherein the BH3 peptide is less than or equal to 25 amino acids in length. 3. The method of claim 1 , wherein the BH3 peptide consists of SEQ ID NO:1.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
- C07K14/4747Primary
Apoptosis related proteins · CPC title
containing a transmembrane segment · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9856303B2 cover?
- The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
- Who is the assignee on this patent?
- Korsmeyer Stanley J, Letai Anthony, Dana Farber Cancer Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/4747. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).